Depression Drug Failure Sets Eli Lilly Back
Insights - Eli Lilly and Company (LLY) on Thursday said it would not seek approval for edivoxetine, an experimental drug to treat major depression, after it failed … Continue Reading
Read NowInsights
Lexicon’s Pipeline Continues to Struggle
Insights - Lexicon Pharmaceuticals (LXRX) announced the latest in a string of disappointments for its development pipeline, but management remains upbeat. On December 3, 2013, the company … Continue Reading
Read Now
OncoMed Shares Soar on Celgene Agreement
Insights - OncoMed (OMED) rose nearly 100% to $27.70 per share on December 3, 2013, when it announced that an agreement with Celgene (CELG) to co-develop and … Continue Reading
Read Now
Baxter and Halozyme resubmit HyQvia to FDA
Insights - If at first you don’t succeed, try again. Baxter Healthcare (BAX) and Halozyme Therapeutics, Inc. (HALO) submitted an amended biologics license application (BLA) to the … Continue Reading
Read Now
Idenix Sues Gilead for Hep-C Patent Infringement
Insights - The turf battle for the lucrative Hepatitis-C market is heating up, not only on the clinical front but also in the courts. Idenix Pharmaceuticals, Inc. … Continue Reading
Read NowLearn about PropThink’s New Look, New Features, and PropThink Premium
Insights - Get Your First Month of PropThink Premium Half-Off Check out the Revamped PropThink.com Two Products Mean the Same Impactful Content at a Lower Price-Point We’re pleased to … Continue Reading
Read Now
On the Back Burner, Sunshine Heart
Insights - In the Tuesday trading session, shares of Sunshine Heart (SSH) briefly touched and bounced from their 200-day moving average at $7.72. SSH, on which PropThink … Continue Reading
Premium: Read Now